Biotech news
Biotech
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important. 1 January 2012
Pharma
The European life sciences industry has a long history. Many of the major players trace their roots to before
the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions. 1 May 2011
Americas
BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future. 1 May 2011
Pharma
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled. 1 May 2011
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007. 1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes. 1 May 2011
Americas
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look. 1 May 2011
Asia
It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains. 1 May 2011
Biotech
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains. 1 May 2011
Biotech
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains. 1 May 2010